{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:59:55Z","timestamp":1753891195662,"version":"3.41.2"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T00:00:00Z","timestamp":1751241600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Gastric cancer (GC) is one of the most common malignancies worldwide. While bone marrow metastasis (BMM) in GC is extremely rare and often complicated by disseminated intravascular coagulation (DIC), a critical condition with a median survival of less than three months in untreated patients. Human epidermal growth factor receptor-2 (HER-2) plays a critical role in GC pathogenesis, and trastuzumab-based regimens have significantly improved outcomes in HER-2 positive metastatic GC. However, the efficacy of immune checkpoint inhibitors (ICIs) in HER-2 positive GC patients with BMM and DIC, particularly those with programmed death-ligand 1 (PD-L1) combined positive score (CPS) &amp;lt;1, remains unclear. Here, we present a case of GC with BMM and DIC that achieved long-term survival through treatment with cadonilimab (an anti-PD-1\/CTLA-4 bispecific antibody) in combination with trastuzumab and chemotherapy. Through this case and literature review, we aim to explore optimal treatment strategies for this rare and challenging subgroup.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case presentation<\/jats:title><jats:p>A 35-year-old woman presented with left hip pain. Imaging and lab tests indicated bone metastasis and DIC. Further evaluation with PET\/CT, gastroscopy, and biopsy confirmed poorly differentiated gastric adenocarcinoma with bone marrow involvement (cT3N+M1, stage IVB). Immunohistochemistry demonstrated PD-L1 CPS &amp;lt;1 and HER-2 (2+), though fluorescence <jats:italic>in situ<\/jats:italic> hybridization (FISH) was negative. Notably, next-generation sequencing (NGS) detected a high plasma HER-2 copy number (34.88). Given her ECOG performance status of 2, initial therapy consisted of trastuzumab combined with docetaxel and fluorouracil, alongside supportive care. Within two weeks, DIC resolved, and pain significantly improved. Treatment was then escalated to a combination of cadonilimab, trastuzumab, and FLOT (5-FU, leucovorin, oxaliplatin, docetaxel). After achieving a partial response, she developed an oxaliplatin allergy, prompting a switch to maintenance therapy with cadonilimab, trastuzumab, and S-1. She achieved progression-free survival (PFS) of nearly 12 months and overall survival (OS) of approximately 15 months, with sustained quality of life throughout treatment course.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This case demonstrates that intensive anti-tumor therapy combining HER-2-targeted agents, ICIs, and chemotherapy, alongside supportive care, can prolong survival and improve life quality in GC patients with BMM and DIC. Hematologic toxicities were the main adverse events but were tolerable, supporting the regimen\u2019s feasibility and safety.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1608636","type":"journal-article","created":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T04:10:20Z","timestamp":1751256620000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Cadonilimab combined with trastuzumab and chemotherapy for HER2-positive gastric cancer with bone marrow metastasis and DIC: a case report and literature review"],"prefix":"10.3389","volume":"16","author":[{"given":"Meijing","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiwen","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danyang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boran","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shubin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gangling","family":"Tong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s13045-023-01451-3","article-title":"Gastric cancer treatment: recent progress and future perspectives","volume":"16","author":"Guan","year":"2023","journal-title":"J Hematol Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1186\/s12911-023-02154-y","article-title":"Optimizing prognostic factors of five-year survival in gastric cancer patients using feature selection techniques with machine learning algorithms: a comparative study","volume":"23","author":"Afrash","year":"2023","journal-title":"BMC Med Inform Decis Mak."},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.5230\/jgc.2014.14.3.164","article-title":"Bone metastasis from gastric cancer: the incidence, clinicopathological features, and influence on survival","volume":"14","author":"Turkoz","year":"2014","journal-title":"J Gastric Cancer."},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.11604\/pamj.2017.28.95.13787","article-title":"Bone metastasis as the first sign of gastric cancer","volume":"28","author":"Ameur","year":"2017","journal-title":"Pan Afr Med J"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12277","article-title":"Bone marrow metastasis from advanced gastric cancer complicated with disseminated intravascular coagulation: a highly aggressive but manageable disease subtype","volume":"42","author":"Zhai","year":"2022","journal-title":"Cancer Commun (Lond)."},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1019702","article-title":"Case report: PD-1 inhibitor-based treatment strategies in gastric cancer complicated by bone marrow metastasis and disseminated intravascular coagulation: A report of two cases","volume":"13","author":"Huang","year":"2023","journal-title":"Front Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s12032-021-01482-1","article-title":"Estimating copy number using next-generation sequencing to determine ERBB2 amplification status","volume":"38","author":"Nakamura","year":"2021","journal-title":"Med Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1049518","article-title":"Patients with positive HER-2 amplification advanced gastroesophageal junction cancer achieved complete response with combined chemotherapy of AK104\/cadonilimab (PD-1\/CTLA-4 bispecific): A case report","volume":"13","author":"Peng","year":"2022","journal-title":"Front Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(23)02033-0","article-title":"Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial","volume":"402","author":"Janjigian","year":"2023","journal-title":"Lancet."},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1259\/bjr\/64677209","article-title":"Gastric carcinoma presenting with extensive bone metastases and marrow infiltration causing extradural spinal haemorrhage","volume":"79","author":"Hussain","year":"2006","journal-title":"Br J Radiol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3978\/j.issn.2078-6891.2014.050","article-title":"Bone marrow infiltration as the initial presentation of gastric signet ring cell adenocarcinoma","volume":"5","author":"Dittus","year":"2014","journal-title":"J Gastrointest Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-016-2051-x","article-title":"Pathological findings in a case of bone marrow carcinosis due to gastric cancer complicated by disseminated intravascular coagulation and thrombotic microangiopathy","volume":"104","author":"Seki","year":"2016","journal-title":"Int J Hematol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-024-03912-y","article-title":"Clinical practice guidelines for management of disseminated intravascular coagulation in Japan 2024. Part 3: solid cancers and vascular abnormalities","volume":"121","author":"Seki","year":"2025","journal-title":"Int J Hematol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1055\/s-0039-1687890","article-title":"Disseminated intravascular coagulation in cancer: an update","volume":"45","author":"Levi","year":"2019","journal-title":"Semin Thromb Hemost."},{"key":"B16","doi-asserted-by":"publisher","first-page":"e13591","DOI":"10.1111\/cpr.13591","article-title":"Single-cell RNA sequencing reveals immune cell dysfunction in the peripheral blood of patients with highly aggressive gastric cancer","volume":"57","author":"Ma","year":"2024","journal-title":"Cell Prolif."},{"key":"B17","article-title":"Disseminated intravascular coagulation in solid tumors: clinical and pathologic study","volume":"86","author":"Sallah","year":"2001","journal-title":"Thromb Haemost."},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.16527","article-title":"Clinicopathologic features and prognosis of 71 patients with gastric cancer and disseminated intravascular coagulation","volume":"11","author":"Chen","year":"2023","journal-title":"PeerJ."},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv508","article-title":"Comprehensive analyses using next-generation sequencing and immunohistochemistry enable precise treatment in advanced gastric cancer","volume":"27","author":"Kuboki","year":"2016","journal-title":"Ann Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmoldx.2016.09.010","article-title":"Next-generation assessment of human epidermal growth factor receptor 2 (ERBB2) amplification status: clinical validation in the context of a hybrid capture-based, comprehensive solid tumor genomic profiling assay","volume":"19","author":"Ross","year":"2017","journal-title":"J Mol Diagn."},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-22-2533","article-title":"HER2 copy number and resistance mechanisms in patients with HER2-positive advanced gastric cancer receiving initial trastuzumab-based therapy in JACOB trial","volume":"29","author":"Pietrantonio","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.2228","article-title":"Efficacy of ipilimumab vs FOLFOX in combination with nivolumab and trastuzumab in patients with previously untreated ERBB2-positive esophagogastric adenocarcinoma: the AIO INTEGA randomized clinical trial","volume":"8","author":"Stein","year":"2022","journal-title":"JAMA Oncol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1007\/s00262-024-03726-1","article-title":"The optimal threshold of PD-L1 combined positive score to predict the benefit of PD-1 antibody plus chemotherapy for patients with HER2-negative gastric adenocarcinoma: a meta-analysis","volume":"73","author":"Li","year":"2024","journal-title":"Cancer Immunol Immunother."},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103967","article-title":"PD-L1 thresholds predict efficacy of immune checkpoint inhibition in first-line treatment of advanced gastroesophageal adenocarcinoma. A systematic review and meta-analysis of seven phase III randomized trials","volume":"9","author":"Formica","year":"2024","journal-title":"ESMO Open"},{"key":"B25","doi-asserted-by":"publisher","first-page":"77","DOI":"10.2217\/17410541.5.1.77","article-title":"Genetic variation and antipsychotic drug effects on serum lipids","volume":"5","author":"Hallman","year":"2008","journal-title":"Per Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1449212","article-title":"Long-term survival of a patient with gastric cancer with bone marrow metastasis receiving S-1 plus oxaliplatin beyond three years: a case report and literature review","volume":"14","author":"Suto","year":"2024","journal-title":"Front Oncol"},{"key":"B27","article-title":"HER2-positive advanced gastric cancer with disseminated intravascular coagulation and diffuse bone marrow carcinomatosis successfully treated with S-1\/trastuzumab chemotherapy\u2013A case report","volume":"42","author":"Senoo","year":"2015","journal-title":"Gan To Kagaku Ryoho."},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn403","article-title":"Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie","volume":"19","author":"Al-Batran","year":"2008","journal-title":"Ann Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(23)00215-2","article-title":"Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study","volume":"24","author":"Van Cutsem","year":"2023","journal-title":"Lancet Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1608636\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T04:10:22Z","timestamp":1751256622000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1608636\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,30]]},"references-count":29,"alternative-id":["10.3389\/fimmu.2025.1608636"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1608636","relation":{},"ISSN":["1664-3224"],"issn-type":[{"type":"electronic","value":"1664-3224"}],"subject":[],"published":{"date-parts":[[2025,6,30]]},"article-number":"1608636"}}